Kiener Peter A 4
4 · Cue Biopharma, Inc. · Filed Nov 17, 2021
Insider Transaction Report
Form 4
Kiener Peter A
Director
Transactions
- Exercise/Conversion
Common Stock
2021-11-16$2.86/sh+1,361$3,892→ 1,361 total - Exercise/Conversion
Stock Option (right to buy)
2021-11-16−1,361→ 105,744 totalExercise: $2.86Exp: 2023-03-23→ Common Stock (1,361 underlying) - Exercise/Conversion
Common Stock
2021-11-15$2.86/sh+18,815$53,811→ 18,815 total - Sale
Common Stock
2021-11-15$17.92/sh−18,815$337,165→ 0 total - Sale
Common Stock
2021-11-16$18.02/sh−1,361$24,525→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2021-11-15−18,815→ 107,105 totalExercise: $2.86Exp: 2023-03-23→ Common Stock (18,815 underlying)
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.86 to $18.31, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The option vests in five equal annual installments beginning March 23, 2017.